Snowy Owl
Retired in 2010, In Memoriam
Sanofi arm may make India global output hub for vaccines
http://economictimes.indiatimes.com...tput_hub_for_vaccines/articleshow/2402836.cms
26 Sep, 2007,
PARIS:
Sanofi Pasteur, the vaccines business of the e28.4-billion Sanofi-Aventis Group, is looking at India as a possible location to set up a global manufacturing base.
The Lyon-based company, which enjoys a 25% global market share in vaccines, has also initiated discussions with Indian pharma companies in this regard.
This is in line with the company?s plans to diversify its global manufacturing locations, particularly in the fast-growing BRIC (Brazil, Russia, India and China) economies. Incidentally, Sanofi Pasteur offers a range of vaccines, providing protection against 20 bacterial and viral diseases.
"We are committed to building global production facility. This is part of the company?s plans to focus on strategic fast-growing economies. We will look at India as any other BRIC country," said Sanofi Pasteur president and CEO Wayne Pisano. He was speaking to ET on the sidelines of an international media event in Paris recently to announce the significant progress in Sanofi-Aventis? R&D pipeline.
Sanofi Pasteur now has four major production sites: Marcy-l?toile (near Lyon) and Val-de-Reuil (near Rouen) in France; in Swiftwater, Pennsylvania in the US and in Toronto, Canada. The 90-acre Marcy-l?toile campus is one of the world?s largest sites dedicated to vaccine research, development and production, with product volumes making up 50% of Sanofi Pasteur?s world production.
Over the past few years, the company has also developed new production sites in China, Thailand, and Argentina, each with its own specific characteristics. This diversification in capabilities is aimed at supporting a reliable supply to meet vaccine demand.
Sanofi pasteur?s wholly-owned Indian subsidiary is into sales and marketing of the company?s portfolio of vaccines. This includes paediatric vaccines in areas like hepatitis B & A, polio, chickenpox as well as adult vaccines for a host of areas like pneumococcal disease and hepatitis B.
In India, 30-40% of Sanofi pasteur?s business comes from the private market where vaccines are generally distributed through pharmacists/physicians. However, the largest chunk of business comes from the public market, where the government and institutional buyers like Unicef, buy vaccines in bulk to distribute amongst economically backward people.
The company currently has an advanced research pipeline in areas like pandemic influenza, seasonal influenza, meningitis and dengue. It has plans to file regulatory submissions over the next few years to the European regulator and US FDA.
http://economictimes.indiatimes.com...tput_hub_for_vaccines/articleshow/2402836.cms
26 Sep, 2007,
PARIS:
Sanofi Pasteur, the vaccines business of the e28.4-billion Sanofi-Aventis Group, is looking at India as a possible location to set up a global manufacturing base.
The Lyon-based company, which enjoys a 25% global market share in vaccines, has also initiated discussions with Indian pharma companies in this regard.
This is in line with the company?s plans to diversify its global manufacturing locations, particularly in the fast-growing BRIC (Brazil, Russia, India and China) economies. Incidentally, Sanofi Pasteur offers a range of vaccines, providing protection against 20 bacterial and viral diseases.
"We are committed to building global production facility. This is part of the company?s plans to focus on strategic fast-growing economies. We will look at India as any other BRIC country," said Sanofi Pasteur president and CEO Wayne Pisano. He was speaking to ET on the sidelines of an international media event in Paris recently to announce the significant progress in Sanofi-Aventis? R&D pipeline.
Sanofi Pasteur now has four major production sites: Marcy-l?toile (near Lyon) and Val-de-Reuil (near Rouen) in France; in Swiftwater, Pennsylvania in the US and in Toronto, Canada. The 90-acre Marcy-l?toile campus is one of the world?s largest sites dedicated to vaccine research, development and production, with product volumes making up 50% of Sanofi Pasteur?s world production.
Over the past few years, the company has also developed new production sites in China, Thailand, and Argentina, each with its own specific characteristics. This diversification in capabilities is aimed at supporting a reliable supply to meet vaccine demand.
Sanofi pasteur?s wholly-owned Indian subsidiary is into sales and marketing of the company?s portfolio of vaccines. This includes paediatric vaccines in areas like hepatitis B & A, polio, chickenpox as well as adult vaccines for a host of areas like pneumococcal disease and hepatitis B.
In India, 30-40% of Sanofi pasteur?s business comes from the private market where vaccines are generally distributed through pharmacists/physicians. However, the largest chunk of business comes from the public market, where the government and institutional buyers like Unicef, buy vaccines in bulk to distribute amongst economically backward people.
The company currently has an advanced research pipeline in areas like pandemic influenza, seasonal influenza, meningitis and dengue. It has plans to file regulatory submissions over the next few years to the European regulator and US FDA.